- Home
- VRCA vs NRXP Comparison
VRCA vs NRXP Comparison
Compare VRCA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 73.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | NRXP |
|---|---|---|
| Price | $8.42 | $2.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 359.1K | ★ 447.9K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | $242,000.00 |
| Revenue This Year | $332.45 | N/A |
| Revenue Next Year | $12.85 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $1.15 |
| 52 Week High | $12.50 | $6.01 |
Technical Indicators
Market Signals| Indicator | VRCA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 70.38 | 47.83 |
| Support Level | $6.26 | $2.22 |
| Resistance Level | $9.82 | $2.53 |
| Average True Range (ATR) | 0.90 | 0.20 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 77.65 | 72.58 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.